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Background: We have shown previously that pan-HDAC inhibitors (HDACIs) m-carboxycinnamic acid
bis-hydroxamide (CBHA) and trichostatin A (TSA) attenuated cardiac hypertrophy in BALB/c mice by inducing
hyper-acetylation of cardiac chromatin that was accompanied by suppression of pro-inflammatory gene networks.
However, it was not feasible to determine the precise contribution of the myocytes- and non-myocytes to
HDACI-induced gene expression in the intact heart. Therefore, the current study was undertaken with a primary
goal of elucidating temporal changes in the transcriptomes of cardiac myocytes exposed to CBHA and TSA.
Results: We incubated H9c2 cardiac myocytes in growth medium containing either of the two HDACIs for 6h and
24h and analyzed changes in gene expression using Illumina microarrays. H9c2 cells exposed to TSA for 6h and 24h
led to differential expression of 468 and 231 genes, respectively. In contrast, cardiac myocytes incubated with CBHA
for 6h and 24h elicited differential expression of 768 and 999 genes, respectively. We analyzed CBHA- and
TSA-induced differentially expressed genes by Ingenuity Pathway (IPA), Kyoto Encyclopedia of Genes and Genomes
(KEGG) and Core_TF programs and discovered that CBHA and TSA impinged on several common gene networks.
Thus, both HDACIs induced a repertoire of signaling kinases (PTEN-PI3K-AKT and MAPK) and transcription factors
(Myc, p53, NFkB and HNF4A) representing canonical TGFβ, TNF-α, IFNγ and IL-6 specific networks. An
overrepresentation of E2F, AP2, EGR1 and SP1 specific motifs was also found in the promoters of the differentially
expressed genes. Apparently, TSA elicited predominantly TGFβ- and TNF-α-intensive gene networks regardless of
the duration of treatment. In contrast, CBHA elicited TNF-α and IFNγ specific networks at 6 h, followed by elicitation
of IL-6 and IFNγ-centered gene networks at 24h.
Conclusions: Our data show that both CBHA and TSA induced similar, but not identical, time-dependent, gene
networks in H9c2 cardiac myocytes. Initially, both HDACIs impinged on numerous genes associated with adipokine
signaling, intracellular metabolism and energetics, and cell cycle. A continued exposure to either CBHA or TSA led
to the emergence of a number of apoptosis- and inflammation-specific gene networks that were apparently
suppressed by both HDACIs. Based on these data we posit that the anti-inflammatory and anti-proliferative actions
of HDACIs are myocyte-intrinsic. These findings advance our understanding of the mechanisms of actions of
HDACIs on cardiac myocytes and reveal potential signaling pathways that may be targeted therapeutically.
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Regulation of gene expression is obligatorily dependent
on the structure of chromatin that is dynamically re-
modeled via posttranslational modifications (e.g., acetyl-
ation, methylation, phosphorylation and ubiquitination)
of its histone and non-histone constituents [1]. Revers-
ible lysine acetylation represents a common modification
of proteins that is carried out by histone acetyl trans-
ferases (HATs) and histone deacetylases (HDACs). The
acetylation of histones leads to de-condensation of chro-
matin that becomes accessible to transcriptional machin-
ery; in contrast, the inert chromatin is enriched in
deacetylated histones [2,3]. Consistent with chromatin
structure-dependent activation of gene expression, many
transcriptional co-activators (e.g., GCN5, PCAF, CBP/
p300) possess HAT activity whereas transcriptional co-
repressors are associated with HDACs. Since DNA-
binding domains are invariably missing from HATs and
HDACs, they are recruited to their target promoters and
enhancers via protein-protein interactions [2,3].
The HDACs represent an ancient super-family of
enzymes conserved from yeast to man. The mammalian
HDACs are divided into the “classical family” of 11 zinc-
dependent hydrolases and the “non-classical family” of
seven NAD+-dependent HDACs called sirtuins. Based
on their phylogeny, domain organization and sub-
cellular localization, the mammalian HDACs are further
split into four sub-classes [4,5]. The HDAC members of
class I (HDAC1, HDAC2, HDAC3 and HDAC8) contain
a central deacetylase domain surrounded by short NH2
and COOH termini. Class I HDACs are mainly localized
in the nucleus and possess potent enzymatic activity to-
ward histones. Six members of Class II are further sub-
grouped into Class IIa (HDAC4, HDAC5, HDAC7 and
HDAC9) and Class IIb (HDAC6 and HDAC10), based
on whether they possess one or two catalytic sites, re-
spectively [4,5]. The class IV consists of a solitary mem-
ber HDAC11, with homologies to Rpd3 and Hda1
proteins of yeast. Finally, sirtuins, the NAD-dependent
lysine deacetylases, belong to Class III [6].
The actions of HATs and HDACs are intimately
involved in the mechanisms of cardiac and skeletal
muscle gene expression [7-10]. A number of studies
have demonstrated a positive therapeutic potential of
HDACIs in animal models of cardiac hypertrophy. The
pan-HDACIs are thought to attenuate pathological car-
diac hypertrophy via their ability to alter chromatin
structure and gene expression in the heart, and in pri-
mary cultures of cardiac myocytes [8,11,12]. It is
believed that by perturbing the epigenetic landscape of
chromatin, the pan-HDAC inhibitors exert genome-wide
changes in both myocytes as well as other cell lineages
in the intact heart. However, the molecular underpin-
ning of the altered gene expression in myocytes versusnon-myocyte cells in the intact heart treated with pan-
HDACIs is poorly understood. The batch-to-batch
variability that is encountered in cardiac myocytes in pri-
mary cultures makes them less suitable to answer this
question with rigor.
The H9c2 cells have emerged as an excellent in vitro
alternative to primary cardiac myocytes. Although lack-
ing the elaborate contractile apparatus of bona fide
cardiac myocytes, H9c2 cells elicit robust hypertrophy-
associated signature of fetal gene expression in response
to angiotensin II, phenylephrine and IL-18; additionally,
akin to what occurs in the intact heart, pathological
hypertrophy of H9c2 cardiac myocytes could be attenu-
ated by pan-HDAC inhibitors, TSA and CBHA [13-16].
This study was undertaken with an objective to deter-
mine genome-wide responses of H9c2 cardiac myocytes
to two distinct pan-HDACIs. We exposed H9c2 cells to
either CBHA or TSA for 6 and 24 h and analyzed their
transcriptomes by whole-genome Illumina microarrays.
We also subjected the differentially expressed genes of
H9c2 cells, induced by CBHA and TSA treatments, to
theoretical analyses using Ingenuity Pathway Analysis
(IPA), Kyoto Encyclopedia of Genes and Genomes
(KEGG) and Core_TF software programs. Our data
revealed that although CBHA and TSA elicited unique
signatures of gene expression at 6h and 24h time points,
both HDACIs suppressed a number of common gene
networks putatively involved in pro-inflammatory causes
and consequences of pathological cardiac hypertrophy.
Results
H9c2 cardiac myocytes constitutively express all major
HDACs and sirtuins
We have shown previously that IL-18-induced patho-
logical hypertrophy in the intact heart and in H9c2 cells
were attenuated by TSA and CBHA that caused hyper-
acetylation of histones in the chromatin both in vivo and
in vitro [14,17]. Modification of histones by pan-HDAC
inhibitors are mediated by their ability to inhibit Class I
and II HDACs; pan-HDAC inhibitors do not affect sir-
tuins [4,5,18]. Since the status of expression of various
HDACs in H9c2 cells in not known, we began these
studies by assessing the expression and sub-cellular
localization of various HDACs and sirtuins in H9c2 cells.
As shown in the representative western blots (Figure 1),
although mono-specific antibodies readily detected all
major HDACs and sirtuins their relative expression and
subcellular localizations in the extracts of H9c2 cells
were quite different. For example, HDAC-1, HDAC-2,
HDAC-3, HDAC-5 and HDAC-7 are mainly localized in
the nucleus of H9c2 cells that elicit nearly equal expres-
sion of HDAC-4 and HDAC-6 in their cytoplasm and
nuclei. Evidently, whereas sirtuin-1, sirtuin-3, sirtuin-4
and sirtuin-6 are primarily localized in the nucleus,
Figure 1 Most HDACs and sirtuins are constitutively expressed in H9c2 rat cardiac myocytes and TSA treatment does not affect their
expression. Total cell extracts from control (C) and trichostatin treated cells (TSA) were probed with monospecific antibodies to the various
enzymes as noted. Nuclear (Nu) and cytoplasmic (Cy) distribution of HDACs and sirtuins were similarly probed. The data are shown for untreated
cells only. TSA-treatment did not change the subcellular distributions (Data not shown).
Table 1 Quantitative PCR measurements of the steady
state levels of various HDACs and sirtuins in H9c2 cells *
Enzyme δCp ( Mean ±SD ) Relative expression
HDAC 1 1.36 ± 0.06 3.9
HDAC 2 0.2 ± 0.004 26.4
HDAC 3 2.26 ± 0.25 2.3
HDAC 4 5.28 ± 0.24 1
HDAC 5 4.92 ± 0.95 1.1
HDAC 6 3.43 ± 0.13 1.5
HDAC 7 2.81 ± 0.28 1.9
Sirtuin 1 6.06 ± 0.38 1.4
Sirtuin 2 2.17 ± 0.38 3.9
Sirtuin 3 6 .00 ± 0.38 1.4
Sirtuin 4 8.43 ± 0.39 1
Sirtuin 5 3.35 ± 0.29 2.5
Sirtuin 6 5.07 ± 0.38 1.7
Sirtuin 7 5.75 ± 0.59 1.5
* qPCR was carried out on total RNA extracted from H9c2 cells grown in serum
free or serum supplemented media. Expression levels were calculated from
δCp values from 3 replicate determinations. Expression levels of various
HDACs were compared to HDAC 4 fixed at 1: similarly fold-changes in the
expression of sirtuins were established against sirtuin 4 whose expression was
fixed at 1.
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Finally, sirtuin-7 seems to be equally distributed in both
cellular compartments (Figure 1). These data suggest
that the subcellular compartmentalization of HDACs
and sirtuins in the H9c2 cardiac myocytes is similar to
that found in many other cells [4,5,18].
We also quantified steady state levels of cognate
mRNAs of various HDACs and situins in H9c2 cells by
qPCR. As shown in Table 1, H9c2 cells expressed
HDAC-1 and HDAC-2 specific mRNAs most abun-
dantly, followed by transcripts encoding HDAC-
3>HDAC-7>HDAC-6>HDAC-5. Similar qPCR analyses
revealed that the constitutive expression of sirtuin-2 spe-
cific mRNA was the highest in H9c2 cells that also
expressed sirtuin-5> sirtuin-6> sirtuin-7> sirtuin-3>sir-
tuin-1>sirtuin-4 specific mRNAs (Table 1). Based on
these and additional quantifications we surmised that
there was a close correspondence between HDAC and
sirtuin proteins and their cognate mRNAs. Additionally,
we observed that exposure of H9c2 cells to the either
pan-HDAC inhibitor affected neither the expression
(Figure 1) nor sub-cellular distribution of HDACs or sir-
tuins (Data not shown).
Pan-HDAC inhibitors alter global gene expression profiles
of H9c2 cells
The main aim of our study was to examine the effect of
HDACIs on gene expression in cardiac myocytes with-
out other cell types (e.g., endothelial cells and fibro-
blasts) that coexist in the intact heart. We serum-starved
H9c2 cells for 16-24h before initiating drug treatment
by incubating the cells in complete growth medium(control) and growth media supplemented with CBHA
or TSA. Based on our empirical assessment of the
actions of HDACIs in “cell cycle-synchronized” H9c2
cells, in the presence or absence of IL-18 [14], we believe
that 6h and 24h time points of treatment will yield snap-
shots of genome-wide actions of CBHA and TSA during
early and late stages of cell cycle. Messenger RNAs
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were processed for hybridization to Illumina rat micro-
arrays and subsequent analysis. We filtered the gene ex-
pression dataset through the criteria of absolute 2-fold
change and p value of <0.01 before analyzing these data
by principal component analysis (PCA) and the un-
supervised hierarchical clustering methods. As shown in
Figures 2 and 3, the cohorts (6 replicates each) of
vehicle-treated H9c2 cells harvested at 6h and 24h oc-
cupy close, albeit unique positions in the PCA graph.
Similarly, the replicates of CBHA- or TSA-treated cells
harvested at 6h and 24 h after treatment are also
uniquely grouped in the PCA graph.
The RatRef-12 Expression BeadChip contains about
21,900 genes. Exposure of H9c2 cells to TSA and
CBHA led to a total of 672 and 1485 differentially
expressed genes, respectively. It appears therefore thatFigure 2 PCA and clustered heat maps of DEGs in the H9c2 cells trea
six independent samples (denoted as colored spheres) of cardiac myocytes
treatment cohort (top panel). The transcriptomic data sets were filtered for
(> 0.99 for all samples for at least one group), fold change in treatment ver
p-values (<0.05) to identify DEGs that were arranged by unsupervised hierathe expression of approximately 3% and 6% of genes
were significantly affected in H9c2 cells in response to
TSA and CBHA, respectively. Based on their temporal
expression characteristics and quantification of their
expression levels, the TSA- and CBHA-responsive
genes could be organized into six distinct clusters, A
through F (Figures 2 and 3). The sizes of Clusters C
and F elicited in TSA-treated cells were much larger
compared with their counterpart clusters in CBHA-
treated cells. This is in contrast to what occurred in
H9c2 cells treated with CBHA that induced more nu-
merous transcripts belonging to Clusters B, D and E.
As depicted in Figure 4, TSA elicited differential ex-
pression of 468 and 231 genes at 6h and 24h post-treat-
ment, respectively. An identical exposure of H9c2 cells
to CBHA for 6h and 24h elicited 768 and 999 DEGs,
respectively.ted with TSA for 6 and 24 h. PCA of gene expression dataset from
treated with TSA for 6 or 24 h shows unique locations of each
significant differential expression based on Illumina detection values
sus control group (>2.0 fold), ANOVA p-values (<0.05) and t-test
rchical clustering (bottom).
Figure 3 PCA and clustered heat maps of DEGs in the H9c2 cells treated with CBHA for 6 and 24 h. PCA of DEGs from six independent
H9c2 cell samples representing CBHA treatment for 6 or 24 h shows unique locations of each treatment cohort (top panel). The heat maps of
DEGs clustered using the statistical criteria described above and in Materials and Methods are shown (bottom).
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perturb overlapping yet distinct gene networks in H9c2
cardiac myocytes
We began our gene network studies with the reasoning
that interrogation of the maximum numbers of DEGs by
IPA would reveal the most robust networks involved in
the actions of TSA or CBHA. Therefore, at first, we
merged all DEGs contained in Clusters A through F into
a single dataset. However, we discovered that the com-
bined dataset was too large for an optimal analysis by
the IPA program and thus, with a goal to reduce the
number of DEGs that could be assessed by IPA, we re-
filtered the TSA- and CBHA-responsive DEGs through
more stringent statistical criteria. We set an absolute
2.5-fold change and p value of <0.01 for TSA-responsive
genes; similarly, CBHA-responsive genes were re-filtered
through an absolute 3.5-fold change and a p value of
<0.01. These statistical maneuvers reduced TSA-regulated genes to 157 and 114, at 6h and 24h post
treatment. Of these, 52 genes were up regulated (33%)
at 6h and 104 genes down regulated (66%). At 24h treat-
ment 52 genes were up regulated (45%) and 62 genes
were down regulated (66%). A more stringent statistical
analysis yielded 147 and 249 genes for CBHA treatment
at 6h and 24h, respectively. At 6h treatment of CBHA
82 genes were up regulated (56%) and 65 genes down-
regulated (44%). At 24h treatment 90 genes were up
regulated (36%) and 159 genes were down regulated
(64%).
The initial analysis of the merged datasets by IPA
revealed that although CBHA and TSA elicited unique
signatures of gene expression, the two pan-HDAC inhi-
bitors also impinged on numerous common gene targets
at 6h (334) and 24h (183) post-treatment (Figure 4). We
also observed that genes in Clusters A through C were
generally up regulated by both HDACIs; in contrast,
Figure 4 Venn diagrams show the number of differentially expressed probe sets elicited in response to CBHA or TSA treatment of
cardiac myocytes for 6 or 24 h. The number of genes affected by CBHA is almost twice that elicited by TSA. There is lesser overlap among the
DEGs elicited early (6 h) and late (24 h) for both TSA and CBHA compared with a much larger number of common transcripts induced by TSA
and CBHA at either time point.
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D through F was repressed by both CBHA and TSA
(Figures 5 and 6).
Next, we combined the top seven IPA networks of
TSA-specific DEGs at 6h and 24h to reveal the hierarchy
of the potential gene networks in the actions of the twoFigure 5 H9c2 cardiac myocytes elicit unique gene expression in resp
and C was up regulated (red) by TSA and CBHA while the expression of gepan-HDACIs (Tables 2 and 3). The DEGs seen after 6h
treatment with TSA revealed the existence of TGFβ (33
connections; 16 focus genes) TNF-α (35 connections; 10
focus genes) and IFNγ (32 connections; 10 focus genes)
specific gene networks (Table 2 and Figure 7). These
cytokine hubs were connected with signaling kinasesonse to TSA or CBHA at 6h. A vast majority of genes in clusters A, B
nes in clusters D, E, and F was suppressed (green) by both HDACIs.
Figure 6 Major genes regulated by TSA or CBHA after 24 h. Incubation of H9c2 cells with either CBHA or TSA for 24 h led to enhanced (red)
expression of most genes in clusters A, B and C while both HDACIs suppressed (green) a vast majority of the transcripts in clusters D, E and F.
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genes) and MAPK (49 connections with 11 focus genes),
and transcription factors (HNF4A; 30 connections with
14 focus genes), (Myc; 30 connections with 12 focus
genes) and (NFkB; 33 connections with 10 focus genes).
We should note here that the inflammatory cytokine
hubs are connected to genes that were either induced or
suppressed by TSA (Figures 5 and 6). Thus, TNF-α spe-
cific hub was connected to HDAC-7, cardiotrophin,
MyoD and Myogenin, all of which were down regulated;
in contrast, the expression of geminin (GMNN) was
induced by TSA (Figure 7). Similarly, the IFNγ specific
hub is connected to both TSA-inducible (XPOT,Table 2 Time-dependent elicitation of cytokine and signaling
Control versus TSA (6 h)







p38-JNK 45 ( 9 )
IFNγ 32 ( 9 )
Caspase 3 28 ( 8 )
CDKN2A 10 ( 8 )
Calcium 31 ( 6 )
Insulin 22 ( 6 )
TP53 20 ( 5 )
*DEGs in response to TSA treatment of H9c2 cells for 6 and 24 h were subject to IP
connections (direct and indirect) and focus genes are hierarchically arranged accord
network elicited at 6 h (13th) and 24 h (4th) is mechanistically significant.caspase-3 and caspase-7) and TSA-suppressible (PKA)
genes. Finally, PTEN specific hub is connected to two
microtubule-associated kinases MAST1 and LIMK1 that
were up regulated by TSA and a transcription factor
(GTF21) that was down regulated in TSA-treated H9c2
cells post 6h treatment. These data are consistent
with our earlier report showing that the expression of
PTEN was highly induced by CBHA in H9c2 cells [14]
and in response to both CBHA and TSA in the intact
heart [17].
A continued exposure to TSA for 24h led to apparent
consolidation of the TGFβ (29 connections with 18 focus
genes) and TNF-α (30 connections; 8 focus genes)pathway by TSA in H9c2 cells*
Control versus TSA (24 h)





TNF-.α 30 ( 8 )
FOS 28 ( 8 )
CDKN1A 12 ( 8 )
NFκΒ 29 ( 3 )
Calcium 28 ( 3 )
AP1 18 ( 3 )
CaMKII 10 ( 3 )
Caspase 3 16 ( 2 )
A as detailed in “Material and Methods”. Gene pathways with total number of
ing to the number of focus genes. The relative order of the p53-specific
Table 3 Key cytokine and signaling pathway elicited in response to CBHA at 6h and 24h in H9c2 cells*
Control versus CBHA (6 h) Control versus CBHA (24 h)
Gene pathway Total connections (No. of focus genes) Gene pathway Total connections (No. of focus genes)
TNF 45 (22) CDKN1A 65 (35)
Myc 43 (18) TP53 60 (35)
HNF4A 32 (18) IL-6 50 (34)
PTEN-PI3K-Akt 76 (17) HNF4A 41 (30)
ERK-p38-JNK 73 (17) CDKN2A 43 (25)
NFκΒ 40 (16) ERK- p38-JNK 52 (21)
IFNγ 45 (12) NFκΒ 41 (17)
FOS 43 ( 8 ) IFNγ 38 (17)
AP1 31 ( 8 ) Cyclin A 29 (12)
Insulin 28 ( 8 ) PI3K-Akt 41 (10)
TP73 16 ( 7 ) MAPK 24 ( 8 )
CDKN2A 20 ( 5 ) Insulin 24 ( 5 )
*DEGs in response to CBHA were subject to IPA as detailed in “Material and Methods”. Gene pathway with total number of connections (direct and indirect) and
focus genes are hierarchically arranged according to the number of focus genes. The relative position of the p53-specific network elicited at 6 h (11th) and 24 h
(2nd) is significant.
Figure 7 Major gene networks specifically modulated by TSA at 6h. The IPA merged the top seven networks of TSA-elicited genes into a
single network. The dominant nodes of TGFβ, HNF-4A, TNFα and MYC connected extensively to the signaling node of NFkB are highlighted. The
major gene networks are either directly (solid lines) or indirectly (broken lines) connected to PI3K- and MAPK-specific signaling pathways. The up
regulated genes are shown in pink and red while down-regulated genes are depicted in green.
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in contrast to a dominant involvement of PTEN-PI3K-
AKT signaling seen at 6h (Table 2), at 24h, MAPK sig-
naling (65 connections; 12 focus molecules) connected
with TGFβ and TNF-α specific hubs was prominent.
There were also unique signal transduction and tran-
scription factor specific networks elicited by TSA at 24
h; thus in addition to HNF4A, TSA strongly induced
Ap1-Jun/Fos (46 connections; 11 focus molecules), p53
(33 connections; 10 focus molecules) and cyclin-
dependent kinases (Table 2 and Figure 8). At 24h treat-
ment, TNF-αspecific gene networks were associated with
regulators of cell cycle (Kif 20A, cyclin A), chromatin
architecture and transcription (MyoG, MyoD, F-actin,
ACTA-1, MCM7); TSA down regulated all these mRNAs.
These gene network analyses are consistent with the
hypothesis that TSA blunted the pro-inflammatory and
pro-fibrotic actions of TNF-α and TGFβ.
Evidently the signaling and transcriptional regulatory
gene networks elicited in CBHA-treated H9c2 cells for
6h or 24h also evolved with treatment duration (Table 3).Figure 8 Major intracellular networks of cardiac genes that were diffe
by TGFβ, TP53, HNF-4A.TNF.α, CDKN1A and NFkB, are highlighted; signalingThe IPA of DEGs of cells treated for 6h with CBHA
revealed the existence of TNF-α (45 connections; 22
focus genes) and IFNγ (45 connections; 12 focus genes)
specific gene networks (Table 3 and Figure 9). These two
cytokine hubs were connected with PTEN-PI3K-AKT
(76 connections; 17 focus genes), MAPK (70 connec-
tions with 14 focus genes), and transcription factors
(Myc; 43 connections with 18 focus genes; HNF4A; 32
connections with 18 focus genes and NFkB; 40 connec-
tions with 16 focus genes). We should note however,
that although PTEN-PI3K-AKT and MAPK signaling
molecules were robustly elicited by both CBHA and
TSA, the cytokine specific networks induced by the two
HDACIs were significantly different in detail. For ex-
ample, while TSA preferentially elicited TGFβ-intensive
gene networks both at 6h and 24h, CBHA treatment eli-
cited strong TNF-α and IFNγ specific networks at 6h
whereas cells exposed for 24h induced IL-6 (50 connec-
tions; 34 focus genes) and IFNγ-centered (38 connec-
tions; 17 focus genes) hubs. Strong CDKN-specific (137
connections; 72 focus genes) and p53-specific (60rentially modulated by TSA at 24h. The dominant nodes, centered
nodes of ERK-JNK-p38MAPK are also present as prominent nodes.
Figure 9 The major gene networks specifically modulated by CBHA at 6h. The IPA merged the top seven networks of CBHA-elicited genes
into a single network. The dominant nodes of IFNγ, HNF-4A, TNFα and MYC connected extensively to the signaling node of NFkB are highlighted.
The major gene networks are either directly (solid lines) or indirectly (broken lines) connected to PI3K- and MAPK-specific signaling pathways. The
up regulated genes are shown in pink and red while down-regulated genes are depicted in green.
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Figure 10) were also seen in CBHA-treated cells at 24h.
A number of unique and shared features of the two
pan-HDACIs are worth mentioning here. First, the TNF-α
specific networks seen in CBHA-treated cells at 6h were
similar to those seen in TSA-treated cells; in both cases
TNF-α specific hubs were directly connected with MyoD,
MyoG, HDAC 7, SERPINB9 genes, all of which were
down regulated (Figure 9). Second, the PTEN specific
gene network, connected to genes that were either
induced (MAST1) or suppressed (PLK1, CDC20 and
GTF21) by CBHA, was only seen at 6h after CBHA treat-
ment. Third, the TP53 gene network was more prominent
in CHBA-treated cells at 24h (60 connections; 35 focus
genes) compared with that seen in TSA-treated cells after
24h. Fourth, numerous DEGs involved in the regula-
tion of cell cycle, chromatin remodeling and mRNA
metabolism were affected by TSA and CBHA. Fi-
nally, it is significant to note that the pro-inflammatory
IFNγ and IL-6 specific gene networks were connected
mainly to down regulated genes involved in DNA replica-
tion cell cycle cell cycle (MCM7, CENT, MCM6, CCNA2,CDC2, CDC6, Cycin A, E2F1) in CBHA-treated cells at
24h.
Ingenuity pathway analyses of six unique clusters of
DEGs corroborate and extend the TSA- and CBHA-
inducible gene networks seen in the combined dataset
As outlined above, the merged dataset was devoid of a
large number of DEGs that were contained in Clusters A
through F. Therefore, to carry out a more comprehen-
sive network analysis with a goal to corroborate and ex-
tend IPA of the merged dataset, we analyzed Clusters A
through F (elicited at 6h and 24h by CBHA and TSA)
individually (Additional files 1, 2, 3, 4: Figures S1-4).
These analyses revealed that, irrespective of the HDACI
or the duration of the treatment, Clusters A, B and C
were populated by genes that regulate intracellular sig-
naling, cellular energetics, inflammation and prolifera-
tion and apoptosis. The TSA-responsive Clusters A-C at
6h (Additional file 1: Figure S1) or 24 h (Additional file 2:
Figure S2) elicited prominent TNF-α, HNF-4A, IFNγ YY1,
Egr1, E2F, and TP53 specific nodes that are connected to
gene networks involved in metabolic regulation, cellular
Figure 10 Major intracellular networks of cardiac genes that were differentially modulated by CBHA at 24h. The dominant nodes,
centered by IL-6, TP53, CDKN1A, CDKN2A, HNF-4A and NFkB are highlighted; signaling nodes of ERK-JNK-p38MAPK are also present as prominent
node.
Majumdar et al. BMC Genomics 2012, 13:709 Page 11 of 20
http://www.biomedcentral.com/1471-2164/13/709energetics and proliferation and apoptosis (SLP1, SPP1,
and DDX5). CBHA-responsive Clusters A-C at 6h (Add-
itional file 3: Figure S3) or 24 h (Additional file 4: Figure
S4) elicited TNF-α IFNγ, NFκB, YY1, E2F and TP53 con-
nected with molecules known to regulate immunity, in-
flammation, intermediary metabolism, and cell growth
(PRKACA, PIK3R2, GNB5, MAPK8IP1, ADIPOR2 and
EGR1). Only Clusters depicting strong networks are
shown. Majority of the genes in Clusters A-C are up regu-
lated by TSA or CBHA irrespective of the duration of
treatment (Figures 5 and 6).
The genes in Clusters D, E and F were repressed by
both pan-HDACIs, regardless of the duration of treat-
ment (Figure 5 and 6). As compared to TSA, CBHA eli-
cited a much larger Cluster D in H9c2 cells (325 versus
95 genes). Cluster D was populated by genes known to
control organization and replication of DNA (e.g.,
POLD1, SMC2 and MCM6), cell cycle (e.g., CCNA,
CCND, BUB1b, CENPE and CDC6) and skeletal muscle
structure (e.g., MYH3, TNNT, TNNC2). Regardless of
the duration of treatment, both CBHA- and TSA-
responsive Cluster D genes formed strong p53, YY1 and
Cyclin-CDK specific networks (Additional files 1, 2, 3, 4;
Figures S1-S4). The regulators of nuclear organization(e.g., NUPR1, HMGA2, and TUBB), cell cycle (e.g.,
CCND1, GTSE and CDC20) and apoptosis (e.g., CARD9
and CASP7) dominated Clusters E and F of cells treated
with either pan-HDAC inhibitor, irrespective of the dur-
ation of treatment. However, the strongest networks in
TSA-responsive genes were demonstrated in Clusters F
involving TNF-α, IL-6 and IFN-γ at 6 and 24h (Add-
itional files 1 and 2; Figures S1 and S2). The CBHA-
responsive genes demonstrated strong networks in Clus-
ters E and formed TNF-α-, IFN-γ-, TP53- and cyclins/
CDK specific gene networks at 6 and 24 h (Additional
files 3 and 4: Figures S3 and S4). We may sum up the
results of IPA of Clusters A through F individually by
concluding that these analyses not only validated the
prediction of IPA of the combined dataset, but also un-
raveled the existence of additional gene networks. Thus,
in addition to the existence of gene networks represent-
ing cytokines (TGFβ1, TNF-α and IFNγ), signal trans-
duction pathways (PTEN-PI3K-AKT and MAPK) and
transcription factors (p53, NFκB and HNF4A), the IPA
of the DEGs in the Clusters A through F unraveled the
putative involvement of Egr1, YY1, E2F, and STAT3 spe-
cific gene networks in the actions of the two pan-HDAC
inhibitors.
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by CBHA and TSA
To extend the in silico examination of the differen-
tially regulated genes by IPA, we subjected DEGs that
were common to TSA and CBHA to KEGG analysis.
The KEGG program is designed to convert the mo-
lecular interactions and gene networks into biologic-
ally functional pathways (Table 4). The KEGG analysis
revealed that CBHA and TSA elicited a number of
overlapping pathways, regardless of the duration of
the treatment (Table 4). Thus, phosphatidylinositol
metabolism and signaling and MAPK pathways were
preeminent in H9c2 cells exposed to either TSA orTable 4 KEGG pathways represented by DEGs commonly regu
DEGs common to TSA and CBHA at 6h
KEGG pathway Gene nos
MAPK signaling pathway 7
Adipocytokine signaling pathway 5
Purine metabolism 5
Cell cycle 5
Phosphatidylinositol signaling system 4
Ubiquitin mediated proteolysis 3
TGF-beta signaling pathway 3
PPAR signaling pathway 3
Pyruvate metabolism 3
Inositol phosphate metabolism 3
Tryptophan metabolism 3
Pyrimidine metabolism 3
Citrate cycle (TCA cycle) 2
Fatty acid metabolism 2
Glutamate metabolism 2
Arginine and proline metabolism 2
Histidine metabolism 2
Tyrosine metabolism 2
Selenoamino acid metabolism 2
Glutathione metabolism 2
DEGs common to TSA and CBHA at 24h
Cell cycle 12
Glutathione metabolism 6





Ubiquitin mediated proteolysis 2
*The KEGG pathways associated with the common gene set affected by TSA or CBH
on the number of common DEGs and the significance of enrichment (p value) derivCBHA at 6h. Furthermore, the putative PTEN-PI3K-
AKT/PKB signaling pathways were connected with
numerous genes involved in the metabolism of pyru-
vate, citrate and amino acids, as well as in the inter-
mediary metabolism of purines and pyrimidines
(Table 4). The emergence of gene networks known to
regulate cell cycle and DNA replication, metabolism
of xenobiotics, oxidative stress and extracellular
matrix were also common in H9c2 cells incubated
with either CBHA or TSA for 24h (Table 4). Based
on these observations we surmise that similar
HDACI-induced gene networks were uncovered by
IPA and KEGG analyses.lated by TSA and CBHA at 6 h or 24 h in H9c2 cells*
Entrez Gene IDs P value
FGF7, FGF8, MKNK2, NFAT4,TGFb3, P=2.02e-3
CD14, MAPKI8P1
CPT1A, PEPCK, ACSL5, ADIPOR2, CAMKK1, P=9.51e-5
NME6, GMPR, IMPDH2, POLD3, POLR3F P=2.90e-3
TGFb3, CUL1, CCNA2, CCNB2, CDC20 P=8.67e-4
IMPA2, INPP4A, PIK3C2A, ITPKA P=1.14e-3
UBE2C, CUL1, CDC20 P=2.88e-3
FST, TGFb3, CUL1 P=1.60e-2
CPT1A, PEPCK, ACSL5 P=1.60e-6
HAGH, PCB, PEPCK P=1.60e-7
IMPA2, INPP4A ITPKA P=1.60e-8
CYP1B1, MAOA, LCMT1 P=1.60e-9









MCM4, MCM3, MCM6 MCM7, PLK1, BUB1B, P=1.74e-14
BUB1 CCNA2, CCNB2 PKMYT1 CDC6, CDC20
GPX7, GST4, GSTM1, GSTP1, GCLC, MGST3 P=1.15e-8
MGST1, GST4, GSTM1, GSTP1, MGST3 P=2.76e-6
POLD1, POLE2, RFC5, RRM2 P=3.95e-4
POLD1, POLE2, RFC5, RRM2 P=2.48e-3
POLD1, POLE2, RFC5 P=1.20e-4
HMMR, LAMC2 P=3.99e-2
UBE2C, CDC20 P=1.19e-2
A at 6h and 24h post-treatment in H9c2 cells are hierarchically arranged based
ed as described in “Material and Methods”.
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of pan-HDAC inhibitors
The network analyses of genes that were differentially
regulated by CBHA and TSA, regardless of whether it
was done by IPA or KEGG programs, strongly predicted
a role of PTEN-PI3K-AKT/PKB and MAPK signaling
pathways in the actions of HDACIs. We reported earlier
that both CBHA and TSA potently induced the expres-
sion of PTEN and concomitant reduction in PI3K and
AKT phosphorylation in H9c2 cells as well as in the in-
tact heart [17]. To test a potential role of MAP kinases,
we extracted proteins from H9c2 cells incubated with
CBHA or TSA for various time intervals and assessed
the steady state levels of total and phosphorylated ERK,
JNK and p38 MAPK. As shown in Figure 11, an expos-
ure to TSA for 4h led to a reduced phosphorylation of
ERK (pERK) and its phosphorylation remained inhibited
until 24h. TSA treatment also significantly suppressed
phosphorylation of p38 (p-p38) as early as 2h. Finally, an
exposure of H9c2 cells to CBHA resulted in a reduction
of pERK at 4h, while the levels of p-p38 kinase were not
significantly affected by CBHA. The temporal changes in
the regulation of JNK in response to CBHA or TSA were
inconclusive (Data not shown). Finally, it should be
noted that neither TSA nor CBHA altered the steady
state levels of total ERK or p38 kinases (Figure 11).Frequency of putative transcription factor binding sites in
differentially expressed genes in response to CBHA and
TSA
With an aim to elucidate potentially common pathways
involved in the induction of genes by CBHA and TSA,
we extended gene network analyses by an in silico exam-
ination of transcription factor binding sites (TFBS) in
the promoters of DEGs. We explored 1 kb of DNAFigure 11 HDAC inhibitors affect phosphorylation of ERK and
p38 in H9c2 cells. Cells were incubated with or without TSA or
CBHA at different time intervals as shown. Ten microgram aliquots
of protein extracts were separated by 10% SDS-PAGE. Western blots
were probed with mono-specific antibodies against phospho-ERK or
p38 MAPK. Blots were stripped, washed and re-probed with anti-ERK
and p38 antibodies. Representative western blots of ERK and p38
MAPK in response to TSA and CBHA are shown.upstream of transcription start site of all differentially
expressed genes by CORE_TF, a web-based program that
identifies dominant TFBS. As shown in Table 5, in DEGs
induced by CBHA at 6 and 24h, the topmost transcrip-
tional factor motifs were those of AP2, CHCH, E2F1,
EGR2 and ETF. An over-representation of AP2, CHCH,
E2F1, EGR2 and ETF was also seen in TSA-treated cells;
additionally, the promoters of the TSA-induced DEGs
expressed zinc finger-containing transcription factors
(Sp1 and KROX). Finally, NF-Y specific motifs were
overrepresented in DEGs induced by TSA at 24h. The
preponderance of E2F1, EGR2, Sp1 and KROX tran-
scription factor binding sites in the DEGs induced by ei-
ther pan-HDAC inhibitor was consistent with an ability
of these transcription factors to regulate genes involved
in cell proliferation and apoptosis. The members of
the E2F family, that bind to RB1, also play a key role
in regulating G to S transition; similarly, NF-Y has a fun-
damental role in the expression of genes that regulate
G2/M phase of the cell cycle.
Discussion
We report here a comprehensive analysis of gene net-
works in H9c2 cells induced in response to two distinct
pan-HDAC inhibitors, TSA and CBHA that have been
shown to attenuate cardiac hypertrophy in vivo and
in vitro [14,17]. Although H9c2 cells differ from bona fide
cardiac myocytes in their inability to elicit well-defined
sarcomeres, they elicit a pathological hypertrophy-specific
gene expression program in response to Angiotensis II,
IL-18 and phenylephrine. Furthermore, pan-HDAC inhi-
bitors alleviated the hypertrophy response of H9c2 cells as
judged by their molecular phenotype [13-15]. We show
that both pan-HDACIs induced intracellular energetics
and pro-inflammatory cytokine specific gene networks
that were connected with canonical signaling kinases
(PTEN-PI3K-AKT/PKB and MAPK) and transcription
factors (e.g., Myc, p53, NFkB and HNF4A) with a wide-
spread potential to regulate the metabolic phenotype,
proliferation and death.
In silico analysis of DEGs by IPA and KEGG programs
indicated that the synthesis and turnover of phosphati-
dylinositol bis- and tris-phosphates (IP2 and IP3) and
their receptors played a prominent role in the actions of
CBHA and TSA. Our observations corroborate and ex-
tend earlier results showing that pan-HDAC inhibitors
blunt the PI3K-AKT signaling by at least two different
mechanisms [17,19,20]. First, it has been reported that
TSA blocked interactions of protein phosphatase-1 with
HDACs 1 and 6; this led to increased dephosphorylation
of pAkt. Secondly, we have demonstrated that pan-
HDACIs CBHA and TSA opposed PI3K-AKT signaling
via inducing PTEN gene expression in cardiac myocytes
as well in the intact hearts. Based on the network
Table 5 Enriched transcription factor binding sites in the promoters of genes, obtained from H9c2 cells treated with
CBHA or TSA*
CBHA 6h
Transcription factors # exp promoters hit # exp promoters P value Q value
AP2_Q6 584 658 0 0
CHCH_01 617 658 0 0
E2F_Q2 548 658 0 0
E2F1_Q3_01 317 658 0 0
EGR2_01 592 658 0 0
ETF_Q6 412 658 0 0
GC_01 584 658 0 0
KROX_Q6 411 658 0 0
LRF_Q2 456 658 0 0
MAZR_01 233 658 0 0
NGFIC_01 434 658 0 0
SP1_Q6_01 558 658 0 0
WT1_Q6 528 658 0 0
AHRHIF_Q6 361 658 1.00E-09 2.25E-08
MUSCLE_INI_B 593 658 1.93E-08 3.97E-07
AHRARNT_02 336 658 1.54E-07 3.03E-06
SPZ1_01 605 658 1.77E-07 3.35E-06
AP2ALPHA_01 596 658 3.81E-07 6.21E-06
AP2GAMMA_01 622 658 3.63E-07 6.21E-06
MAZ_Q6 315 658 3.70E-07 6.21E-06
UF1H3BETA_Q6 31 658 1.20E-05 1.89E-04
CACBINDINGPROTEIN_Q6 431 658 1.26E-05 1.92E-04
MOVOB_01 647 658 3.16E-05 4.44E-04
VDR_Q3 603 658 3.42E-05 4.62E-04
ZF5_B 655 658 9.53E-05 1.25E-03
E2F1DP2_01 293 658 1.48E-04 1.89E-03
NFY_Q6_01 226 658 2.11E-04 2.62E-03
CACD_01 635 658 2.61E-04 3.16E-03
MZF1_02 571 658 3.58E-04 4.23E-03
CACCCBINDINGFACTOR_Q6 78 658 4.56E-04 5.26E-03
WHN_B 145 658 4.92E-04 5.54E-03
CBHA 24h
AP2_Q6 728 847 0 0
AP2ALPHA_01 776 847 0 0
CHCH_01 794 847 0 0
E2F_Q2 680 847 0 0
E2F1_Q3_01 379 847 0 0
EGR_Q6 604 847 0 0
ETF_Q6 492 847 0 0
GC_01 737 847 0 0
KROX_Q6 486 847 0 0
MAZR_01 256 847 0 0
NGFIC_01 532 847 0 0
SP1_01 697 847 0 0
WT1_Q6 682 847 0 0
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Table 5 Enriched transcription factor binding sites in the promoters of genes, obtained from H9c2 cells treated with
CBHA or TSA* (Continued)
LRF_Q2 559 847 2.00E-10 4.68E-09
MZF1_02 759 847 2.00E-10 4.68E-09
SPZ1_01 780 847 1.80E-09 4.02E-08
AP2GAMMA_01 802 847 3.60E-09 7.33E-08
MOVOB_01 837 847 1.79E-08 3.49E-07
CACBINDINGPROTEIN_Q6 555 847 8.55E-07 1.48E-05
CACD_01 822 847 1.19E-06 1.99E-05
CACCCBINDINGFACTOR_Q6 108 847 2.31E-06 3.72E-05
AHRHIF_Q6 431 847 3.66E-06 5.53E-05
NFY_Q6_01 294 847 1.24E-05 1.77E-04
E2F1DP2_01 378 847 1.64E-05 2.26E-04
AHRARNT_02 408 847 1.99E-05 2.67E-04
MAZ_Q6 382 847 3.46E-05 4.51E-04
STRA13_01 32 847 8.99E-05 1.08E-03
SP3_Q3 821 847 3.89E-04 4.14E-03
VDR_Q3 766 847 4.08E-04 4.24E-03
MUSCLE_INI_B 733 847 7.95E-04 8.10E-03
TSA 6h
E2F_Q2 319 390 0 0
E2F1_Q3_01 187 390 0 0
ETF_Q6 243 390 0 0
GC_01 341 390 0 0
KROX_Q6 233 390 0 0
SP1_Q6_01 320 390 0 0
CHCH_01 361 390 8.00E-10 3.33E-08
MAZR_01 128 390 1.70E-09 6.52E-08
EGR2_01 350 390 1.66E-08 5.52E-07
WT1_Q6 309 390 6.34E-08 1.98E-06
NGFIC_01 249 390 8.85E-08 2.60E-06
AP2_Q6 334 390 7.62E-07 2.00E-05
LRF_Q2 262 390 8.74E-07 2.18E-05
UF1H3BETA_Q6 20 390 8.70E-05 2.07E-03
AHRHIF_Q6 205 390 9.40E-05 2.10E-03
AHRARNT_02 195 390 1.99E-04 4.14E-03
MAZ_Q6 183 390 2.74E-04 5.48E-03
ZEC_01 2 390 3.48E-04 6.69E-03
TSA 24h
GC_01 161 194 1.45E-05 2.49E-03
NFY_01 118 194 9.66E-06 2.49E-03
E2F_Q2 141 194 4.78E-05 4.94E-03
SP1_Q2_01 143 194 8.48E-05 7.30E-03
* Overrepresented transcription factor binding sites were found in genes obtained from H9C2 cells induced with CBHA and TSA at different time points using
CORE_TF. Differential expression of genes was considered to obtain the genes with 2 fold change.
* Experimental promoters hit shows the number of genes which have that TFBS in their promoter region, from the total number of genes scanned.
* One-tailed Mann–Whitney rank sum p value.
* Multiple testing corrected false discovery rate (FDR) q value, here q value <0.01.
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gene networks regulate cell cycle and growth via PLK1,
CDC20, MAST1 and LIMK1 kinases.
An extensive review of the literature indicates that
HDACIs are capable of blunting the inflammatory re-
sponse in a number of pathological settings [21]. Appar-
ently, several signaling kinases, including MAPKs,
participate in the anti-inflammatory actions of pan-
HDACIs. It is significant therefore that both CBHA and
TSA inhibited the activation of ERK and TSA inhibited
phosphorylation of p38 MAPK in H9c2 cells in a time
dependent manner. Earlier observations have also shown
that PI3K and MAPK signaling are engaged in extensive
crosstalk in the patho-physiology of the heart [22-27].
The activation of ERK via phosphorylation was asso-
ciated with neoplastic transformation that was inhibited
by TSA [28]. Similarly, TSA could also block the activa-
tion of ERK signaling induced by TGF-β [19].
We have reported previously that CBHA induced
hyper-acetylation of histone H3 (H3-K9) and inhibited
its phosphorylation (H3-S10) in IL-18 treated cells [14].
Both CBHA and TSA elicited similar posttranslational
modifications of histones in the cardiac chromatin [17].
It has been suggested by Saccani and coauthors that p38
dependent phosphorylation of histone H3 may mark
promoters for increased NF-kB recruitment [29]. Based
on our limited analysis of changes in the phposphoryla-
tin and acetylation of p65 subunit of NFkB in H9c2 cell
treated with CBHA or TSA (Data not shown), we posit
that both HDACIs could alter NF-kB recruitment to
selected chromatin targets in these cells. These data
must be tempered with caution and precise link between
NFkB and suppression of anti-inflammatory gene net-
works by CBHA and TSA remains in the realm of
speculation. This is because the regulation of NFkB, con-
sisting of dimeric permutations of c-Rel, RelA, RelB,
p50, and p52 subunits, via acetylation is highly complex
and context-dependent [30-32].
The cardinal features of maladaptive cardiac hyper-
trophy include (i) a major shift from fatty acid to glucose
oxidation as the main source of fuel [8,33,34], (ii)
increased size and contractility of myocytes, and (iii) ex-
cessive accumulation of extracellular matrix and fibrosis
[35-37]. The induction of TNF-α IFNγ, IL-6, and TGFβ
specific gene networks in the cardiac myocytes in re-
sponse to TSA and CBHA suggests that HDACIs are
capable of interfering with cell proliferation (apoptosis
and autophagy), pro-inflammatory [38-40] and pro-
fibrotic [33,41] mechanisms. Both IPA and KEGG ana-
lyses also unraveled a striking effect of HDACIs on the
metabolism of lipids, carbohydrates, amino acids, pur-
ines and pyrimidines, as well as on the metabolism of
glutathione and xenobiotics. The potential reprogram-
ming of gene expression by HDACIs to elicit the genenetworks observed here would be expected to alle-
viate metabolic consequences of pathological cardiac
hypertrophy.
Recent observations have demonstrated that pan-
HDACIs not only enhance acetylation of histones, but
also of numerous other proteins that include transcrip-
tion factors and enzymes involved in glycolysis, gluco-
neogenesis and fat and glycogen metabolism [9,42-47].
With regard to the phenotypic changes seen in H9c2
cells treated with CBHA and TSA, it is evident that the
signaling cascades induced by both HDACIs culminated
in the nucleus to re-program expression of genes that
control growth and differentiation (i.e., HDAC7, CBP/
p300, NFATc4, MEF-2, myogenin and MyoD) and archi-
tecture (i.e., myosin, skeletal muscle actin, tubulin and
vimentin) of cardiac myocytes. It was also evident that
both CBHA and TSA impinged on a number of com-
mon transcription factors Myc, p53, HNF4A and NFkB
(predicted by IPA) and E2F, EGR2, AP2, and ETF (pre-
dicted by Core_TF), that are known to modulate the ex-
pression of genes that regulate S, G and M phases of the
cell cycle [48-53]. A role of NFkB in the protection of
cardiac myocytes from inflammatory signals, both
in vitro and in vivo is well established; HDACIs are
known to regulate NFkB signaling [11,40,54].
We should note that in silico predictions of the IPA
and CORE_TF programs with respect to the putative
transcription factors are limited in two ways. First, these
analyses only provide a snapshot of transcription at 6h
and 24h and need to be extended on both sides of the
timescale used here. Second, the exact dynamics of in-
duction of various TFs need to be experimentally vali-
dated. With these caveats notwithstanding, it is
noteworthy that the preponderance of the TFs involved
in the regulation of gene expression in response to TSA
or CBHA were not identical. Thus, the IPA predicted
HNF4A, Myc, p53 and NFkB to be the dominant tran-
scription factors; in contrast, the Core_TF program pre-
dicted the preponderance of E2F1, AP2, EGR2, ETF, Sp1
and KROX. These apparently dissimilar predictions of
TFBS that mediate epigenetic regulation of DEGs likely
reflect the uniqueness of the two programs. The IPA
assigns nodes in gene network using focus molecules
and their known relationships based on published obser-
vations stored in the Ingenuity Pathways Knowledge
Base. In contrast CORE_TF program uses the focus
genes exclusively and directly interrogates their promo-
ters for TFBS. Nevertheless, both IPA and Core_TF pro-
grams give complementary information on the common
biological processes (e. g., proliferation, cell cycle and
apoptosis) by pan-HDAC inhibitors. The known regula-
tory interrelationships among the dominant TFs pre-
dicted by IPA and Core_TF support this notion. For
instance, NFkB is known to interact with the regulatory
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of cell cycle regulation. Similarly, Myc regulates the ex-
pression of E2F via cyclin D1. A differential expression
of p53 and CDKNA predicted by IPA is highly signifi-
cant. The regulation of p53 expression is mechanistically
linked to E2F (a key transcription factor predicted by
Core_TF), CDKs and cyclins. The p53 also forms a
prominent network that directly connects it to p21 and
cyclin D1 both of which are involved in the regulation of
E2F, NF-Y and ETF transcription factors. Finally, it
should be noted that cyclins, CCNA2, CDC2 and her-
pud1 are bona fide targets of NF-Y regulation.
Conclusions
Based on these data we conclude that pan-HDAC inhibi-
tors impinge on a number of key regulatory gene net-
works to profoundly alter the phenotype of H9c2 cardiac
myocytes to facilitate their survival in the face of poten-
tial inflammatory pathways evoked by pro hypertrophy
agents (e.g., phenylephrine, Ang-II and IL-18). The
cytokine-specific gene networks, signaling pathways and
transcription factors putatively perturbed by pan-HDAC
inhibitors reported here provide a potential platform to
test a number of hypotheses related to the known speci-




H9c2 cells were purchased from American Type Culture
Collection, Bethesda MD, were grown in Dulbecco’s
minimum essential medium (DMEM) containing 10%
fetal bovine serum (Hyclone, Logan, UT), 2 mM glutam-
ine and 1% Penicillin/Streptomycin. Cells were allowed
to reach about 80% confluence in complete culture
medium. The cultures were incubated for additional 24h
in serum-free medium prior to experimental treatments,
as outlined previously [14]. Six replicate cultures of
H9c2 cells each were treated with either CBHA (1 μM)
or TSA (100 nM); aliquots of parallel cultures incubated
in complete growth medium for 6h and 24h served as
control for gene expression analysis.
Gene expression profiling
RNA was extracted from H9c2 cells by the Trizol method
followed by a cleaning up of RNA samples with an RNeasy
clean up kit (Qiagen Inc., Valencia, CA). The total yield
and quality of RNAs were established by measuring ab-
sorbance at 260nm/280nm in a spectrophotometer and
size-fractionation by electrophoresis in 1% agarose gels,
respectively. Two hundred ng aliquots of total RNA per
sample were used for cDNA and cRNA synthesis; we used
IlluminaW TotalPrepTM RNA Amplification Kit (AppliedBiosystems/Ambion, Austin, TX). Aliquots of amplified
and labeled cRNA (750–1500 ng) were hybridized to Illu-
mina RatRef-12 Expression BeadChips containing
>22,000 transcripts (Illumina Inc., San Diego, CA). After
washing and staining, chips were scanned on the Illumina
500GX BeadArray Reader using Illumina BeadScan image
data acquisition software. The data acquisition, processing
and normalization of the microarray data were done with
Illumina GenomeStudio software (version 1.5.10) to gen-
erate an output file for statistical analysis.
Statistical analyses of differential gene expression
Statistical, mulitvariate and clustering analyses were per-
formed in GeneMaths XT (Applied Maths, Belgium).
The identification of differentially expressed genes was
based on (1) Illumina detection values ≥ 0.99 for all sam-
ples in at least one experimental or control group and
(2) ANOVA p-value ≤0.01; 3), absolute fold change ≥2.0
and independent t-test p-value ≤ 0.01 for any experi-
mental group versus its respective control group. Princi-
pal component analysis (PCA) was performed using
signal values for probe sets with detection values ≥0.99
for all samples in at least one experimental or control
group; signal values were log2 transformed and standar-
dized by row mean centering prior to PCA. Unsuper-
vised hierarchical clustering of DEGs was performed
using UPGMA method (Un-weighted Pair Group
Method using Arithmetic averages) that uses Euclidean
distance as the similarity metric. Sample clustering was
done using Complete Linkage method with Pearson cor-
relation as the similarity metric. Venn diagrams were
generated by Boolean intersection of gene IDs for DEGs
from the indicated pair-wise comparisons.
Bioinformatics analyses
Gene annotation and Gene Ontology (GO) were
obtained from the National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov) and the Gene
Ontology Consortium (http://amigo.geneontology.org).
Analyses of GO enrichment and KEGG (Kyoto
Encyclopedia of Genes and Genomes; www.genome.
jp/kegg) biochemical pathways were performed using
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt).
Hypergeometric test p-values were used to estimate
the significance of enrichment of specific GO catego-
ries or pathways.To search for over-represented tran-
scription factor binding sites (TFBS) in the DEGs
induced by HDACIs, we used a web-based program
CORE_TF (55) (http://www.LGTC.nl/CORE_TF). This
program was used to search for common TF binding
motifs, derived from postion based matrices from the
TRANSFACR database. The search for TFBS was
restricted to the 1000 bases upstream of the tran-
scription start site (TSS). The output p-values and
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false discovery rate of 1%. The methods have been
detailed previously [55].
Ingenuity pathways analysis
The canonical network models of DEGs were developed
using the IPA (version 8.7) (www.ingenuity.com) as out-
lined in detail previously [17]. The Illumina gene lists
were uploaded as a text file and each gene identifier was
mapped to its corresponding gene object. An initial gene
set of DEGs was first overlaid onto the set of all catalo-
gued interactions and focus genes contained in the IPA
library of canonical pathways. To start building net-
works, the application queries the Ingenuity Pathways
Knowledge Base for interactions between Focus Genes
and all other gene objects stored in the knowledge base
and generates a set of networks each with no more than
35 genes/proteins. The IPA then computes a score for
each network according to the fit of the user’s set of sig-
nificant genes. The score is derived from a p value that
denotes the likelihood of a Focus Gene’s presence in a
network due to chance. The networks graphically denote
nodes and edges, or lines (the biological relationships
between the nodes). Assignment of nodes in gene net-
work is made using published observations stored in the
Ingenuity Pathways Knowledge Base. A Fischer’s exact
test was used to calculate a p value predicting the prob-
ability that the biological function assigned to that net-
work is explained by chance alone.
PCR-based quantification of gene expression
RNA was extracted from control or treated H9c2 cardiac
myocytes using TRIzol RNA extraction reagent (Invitro-
gen Life Technologies). Total RNA was precipitated with
ethanol, concentrated by centrifugation and dissolved in
diethylpyrocarbonate (DEPC)-treated water. Aliquots of
800 ng of RNA were used to synthesize cDNA (Super-
Script III, Invitrogen). Gene-specific primers and Taq-
Man probes for quantitative RT-PCR (Q-PCR) were
designed using Universal Probe Library (Roche) as
detailed previously [17]. The Cp values for each HDAC
and Sirtuin gene were normalized to the Cq values of
the constitutively expressed ß-actin gene.
Western blot analysis
Total proteins from H9c2 cells were extracted using
radio-immunoprecipitation (RIPA) buffer according to
the manufacturer’s protocol (Santa Cruz Biotechnology,
CA). The nuclear and cytoplasmic and fractions were
separated using the NE-PERTM (www.thermo.com/
pierce) method [56]. For western blot analysis, equal
amounts of protein from each sample were separated
using 10% SDS-PAGE. After electrophoresis, the protein
samples were transferred to Immobilon-P membranes(Millipore Corp., Bedford, MA) using a Trans-Blot elec-
trophoresis transfer cell (Bio-Rad Laboratories, Inc.,
Hercules, CA). Various HDACs, sirtuins and MAP
kinases were detected on western blots with mono-
specific primary antibodies (Santa Cruz). Anti-ERK, anti-
phospho-ERK or anti-phospho-p38 antibodies were
obtained from Cell Signaling Technology (Beverly, MA).
The blots were sequentially reacted with primary anti-
bodies followed by horseradish peroxidase-conjugated
anti-rabbit IgG antibodies according to manufacturer’s
instructions (Santa Cruz). Chemi-luminescence signals
developed using ECL Plus kit (Amersham-Pharmacia
Biotech, Piscataway, NJ). Some blots were stripped and
re-probed with anti-ERK or p38 antibodies to determine
equivalency of protein loading. The data from 3–4 repli-
cate experiments were quantified by densitometry, nor-
malized against total ERK or p38 or actin, and subjected
to statistical analysis, as outlined previously [14,57].
Additional files
Additional file 1: Figure S1. Major gene networks formed by DEGs in
Clusters A-F in H9c2 cells treated with TSA for 6 h. Cluster A formed gene
network with INF γ TP53andAkt as central nodes connected by direct
(solid lines) or indirect (broken lines) to genes that were either up
regulated (pink and red) or down regulated (green). Cluster C showed
the intracellular gene networks with TNFα, MYC and TP53 and the
signaling molecules ERK-JNK-p38MAPK and NFκB forming the central
nodes. Cluster D had dominant gene network specifying TP53 and YY1
as the central nodes. Clusters F demonstrated TNFα and IL-6 as major
nodes connected to mostly down regulated genes (green).
Additional file 2: Figure S2. IPA of DEGs in Clusters A-F induced by
TSA in H9c2 cells at 24 h. Cluster A demonstrated the intracellular gene
network with TNF-α, MYC, FOS, HNF-4A and TP53 and the signaling
molecules PI3K-Akt-ERK-JNK-p38MAPK and NFκB forming the central
nodes. Cluster C demonstrated the intracellular gene networks with TNF-
α, TP53, MYC and HNF-4A and the signaling molecules PI3K-Akt-ERK-JNK-
p38MAPK and NFκB as the central nodes. Cluster D demonstrated TGFβ,
TP53 and CDKN1A genes as the central nodes in the gene network.
Cluster F demonstrated TNF-α and INFγ connected with the signaling
nodes of PI3K-AKT- ERK-JNK-p38MAPK and NFκB.
Additional file 3: Figure S3. Intracellular gene networks formed by
DEGs in Clusters A-F in H9c2 cells in response to CBHA treatment for 6 h.
Cluster A formed dominant gene networks with TNF-α INFγ and TP53 as
the central nodes connected directly (solid lines) or indirectly (broken
lines) to genes that were either up regulated (pink and red) or down
regulated (green). Cluster B depicted TNFα, INΦγ, TP53 and MYC as the
central nodes in the gene network. Cluster D demonstrated TP53 and
CDKN1A genes as the central nodes in the gene network. Cluster E
displayed the dominant nodes, centered by TNF−α TP53, CDKN1A and
INFγ.
Additional file 4: Figure S4. Major gene networks formed by DEGs in
Cluster A-F in H9c2 cells in response to CBHA treatments for 24 h. Cluster
A formed gene networks with TNF−α and the signaling nodes PI3K-AKT-
JNK and NFκB. Cluster B depicted TNF-α, INFγ, TP53, MYC and CDKN2A
and the signaling molecules PI3K-Akt-ERK-JNK-p38MAPK and NFκB as the
central nodes in the gene network. Cluster D demonstrated TP53, YY1
and CDKN1A genes as the central nodes in the gene network. Cluster E
displayed the dominant nodes, centered by TNF-α, ΙNFγ TP53 and
CDKN1A.
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